USNA USANA HEALTH SCIENCES INC
Medicinal Chemicals & Botanical Products · NYSE · SEC CIK 896264 · Fiscal year ends 01/03
Financial factors as of 2026-10-03 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-0.8%
TTM net income YoY-224.8%
TTM EPS YoY-226.7%
Revenue 3-yr CAGR-0.8%
Net income 3-yr CAGR—
Margins
Gross margin77.3%
Operating margin-0.4%
Net margin-2.3%
FCF margin3.3%
EBITDA margin3.2%
Returns
ROE-4.0%
ROA-3.0%
ROIC (approx.)-0.8%
Asset turnover1.26x
Leverage & solvency
Liabilities / assets19.5%
Debt / equity0.00x
Current ratio2.59x
Interest coverage-9.35x
Cash quality & payout
Operating cash flow / net income-1.96x
Accruals ratio-8.8%
Payout ratio—
Capex / revenue1.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252026-01-03 | FY20232024-12-28 | FY20232023-12-30 | FY20222022-12-31 | FY20222022-01-01 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $925.26M | $854.50M | $921.01M | $998.60M | $1.19B |
| Cost of revenue | $200.85M | $161.21M | $176.69M | $193.89M | $217.90M |
| Gross profit | $724.40M | $693.29M | $744.32M | $804.71M | $968.57M |
| R&D expense | $10.69M | $11.57M | $11.45M | $11.56M | $11.11M |
| SG&A expense | $337.37M | $263.27M | $256.99M | $262.30M | $279.11M |
| Operating income | $37.43M | $66.32M | $93.07M | $107.61M | $170.19M |
| Interest expense | $842,000 | $281,000 | $262,000 | $192,000 | $57,000 |
| Pretax income | $41.53M | $76.35M | $102.45M | $108.62M | $170.64M |
| Income tax | $30.05M | $34.29M | $38.66M | $39.27M | $54.14M |
| Net income | $10.76M | $42.03M | $63.79M | $69.35M | $116.50M |
| EBITDA | $69.99M | $80.86M | $105.77M | $121.01M | $183.23M |
| EPS (basic) | 0.58 | 2.20 | 3.31 | 3.60 | 5.78 |
| EPS (diluted) | 0.58 | 2.19 | 3.30 | 3.59 | 5.73 |
| Weighted avg. shares (diluted) | 18.57M | 19.16M | 19.34M | 19.31M | 20.34M |
| Balance sheet | |||||
| Cash & equivalents | $158.38M | $181.77M | $330.42M | $288.42M | $239.83M |
| Receivables | $4.29M | — | — | — | — |
| Inventory | $102.61M | $69.73M | $61.45M | $67.09M | $98.32M |
| Current assets | $288.40M | $279.19M | $417.75M | $384.38M | $365.12M |
| PP&E, net | $94.38M | $94.56M | $99.81M | $97.77M | $101.78M |
| Goodwill | $137.96M | $144.17M | $17.10M | $17.37M | $17.67M |
| Intangibles | $133.15M | $151.82M | $29.92M | $32.43M | $30.44M |
| Total assets | $742.91M | $748.19M | $632.76M | $596.55M | $577.74M |
| Current liabilities | $128.56M | $139.62M | $118.84M | $143.83M | $160.79M |
| Total liabilities | $156.64M | $161.86M | $135.56M | $162.08M | $182.62M |
| Shareholders' equity | $533.10M | $532.11M | $497.20M | $434.47M | $395.12M |
| Shares outstanding | 18.28M | 19.06M | 19.13M | 19.21M | 19.39M |
| Cash flow statement | |||||
| Operating cash flow | $22.35M | $60.99M | $70.64M | $103.90M | $121.23M |
| Capital expenditure | $13.82M | $10.07M | $14.49M | $10.40M | $12.76M |
| Free cash flow | $8.53M | $50.92M | $56.15M | $93.50M | $108.46M |
| Investing cash flow | -$10.12M | -$213.09M | -$11.97M | -$12.37M | -$14.19M |
| Financing cash flow | -$40.60M | $9.55M | -$14.24M | -$30.09M | -$181.41M |
| Depreciation & amortization | $32.56M | $14.54M | $12.70M | $13.39M | $13.04M |
| Stock-based compensation | $13.83M | $14.56M | $14.60M | $13.33M | $14.30M |
| Share buybacks | $27.51M | $9.44M | $11.60M | $25.38M | $177.84M |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.